Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance

References

• Astrup, A. and Finer, N. 2000. Redefining Type 2 diabetes: ‘Diabesity’ or ‘obesity dependent diabetes mellitus’? Obes Rev 1:57–59.
   PubMedGoogle Scholar
• Balfour, J. A. and Plosker, G. L. 1999. Rosiglitazone. Drugs 57:921–30; discussion 931.
   PubMed Web of Science ®Google Scholar
• Bennett, P. H. 1983. The diagnosis of diabetes: New international classification and diagnostic criteria. Annu Rev Med 34:295–309.
   PubMed Web of Science ®Google Scholar
• Berntorp, K., Trell, E., Thorell, J. and Hood, B. 1983. Relation between plasma insulin and blood glucose in a cross-sectional population study of the oral glucose tolerance test. Acta Endocrinol 102:549–556.
   PubMedGoogle Scholar
• Bligh, E. G. and Dyer, W. J. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917.
   PubMedGoogle Scholar
• Bogacka, I., Xie, H., Bray, G. A. and Smith, S. R.. 2004. The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27:1660–1667.
   PubMed Web of Science ®Google Scholar
• Bogacka, I., Xie, H., Bray, G. A. and Smith, S. R. 2005. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54:1392–1399.
   PubMed Web of Science ®Google Scholar
• Bulcão, C., Giuffrida, F. M., Ribeiro-Filho, F. F. and Ferreira, S. R. 2007. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res 40:229–235.
   PubMed Web of Science ®Google Scholar
• Chu, C. S., Lee, K. T., Lee, M. Y., Su, H. M., Voon, W. C., Sheu, S. H. and Lai, W. T.. 2006. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Am J Cardiol 97:646–650.
   PubMed Web of Science ®Google Scholar
• Colca, J. R., Dailey, C. F., Palazuk, B. J., Hillman, R. M., Dinh, D. M., Melchior, G. W. and Spilman, C. H. 1991. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes 40:1669–1674.
   PubMed Web of Science ®Google Scholar
• Devaraj, S., Siegel, D. and Jialal, I. 2007. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 100:1397–1399.
   PubMed Web of Science ®Google Scholar
• Ding, S. Y., Shen, Z. F., Chen, Y. T., Sun, S. J., Liu, Q. and Xie, M. Z. 2005. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin 26:575–580.
   PubMed Web of Science ®Google Scholar
• El Gawly, H. W., Tawfik, M. K., Rashwan, M. E. and Baruzaig, A. S. 2009. The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats. Eur Rev Med Pharmacol Sci 13:443–451.
   PubMed Web of Science ®Google Scholar
• Esteve, E., Ricart, W. and Fernández-Real, J. M. 2009. Adipocytokines and insulin resistance: The possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 32 Suppl 2:S362–S367.
   PubMed Web of Science ®Google Scholar
• Forst, T., Pfutzner, A., Lubben, G., Weber, M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C. and Hanefeld, M. 2007. Effect of simvastatin/pioglitazone on insulin resistance, insulin secretion, adiponectin, and pro-insulin levels in non-diabetic patients at cardiovascular risk—the PIOSTAT Study. Metabolism 56:491–496.
   PubMed Web of Science ®Google Scholar
• Freed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R. and Brunzell, J. D. Rosiglitazone Study 108 investigators. 2002. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am J Cardiol 90:947–952.
   PubMed Web of Science ®Google Scholar
• Goldstein, B. J. and Scalia, R. 2004. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563–2568.
   PubMed Web of Science ®Google Scholar
• González-Sánchez, J. L., Zabena, C. A., Martínez-Larrad, M. T., Fernández-Pérez, C., Pérez-Barba, M., Laakso, M. and Serrano-Ríos, M. 2005. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res 13:807–812.
   PubMedGoogle Scholar
• Greenberg, A. S. and Obin, M. S. 2006. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461S–465S.
   PubMed Web of Science ®Google Scholar
• Guilherme, A., Virbasius, J. V., Puri, V. and Czech, M. P.. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and Type 2 diabetes. Nat Rev Mol Cell Biol 9:367–377.
   PubMed Web of Science ®Google Scholar
• Guo, Z. and Zhou, L. 2004. Evidence for increased and insulin-resistant lipolysis in skeletal muscle of high-fat-fed rats. Metab Clin Exp 53:794–798.
   PubMed Web of Science ®Google Scholar
• Hajer, G. R., van Haeften, T. W. and Visseren, F. L. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29:2959–2971.
   PubMed Web of Science ®Google Scholar
• Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., Stier, U. and Forst, T. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol 49:290–297.
   PubMed Web of Science ®Google Scholar
• Horio, F., Teradaira, S., Imamura, T., Anunciado, R. V., Kobayashi, M., Namikawa, T. and Niki, I. 2005. The HND mouse, a nonobese model of Type 2 diabetes mellitus with impaired insulin secretion. Eur J Endocrinol 153:971–979.
   PubMed Web of Science ®Google Scholar
• Hu, E., Liang, P. and Spiegelman, B. M. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703.
   PubMed Web of Science ®Google Scholar
• Hwu, C. M., Kwok, C. F., Chen, H. S., Shih, K. C., Lee, S. H., Hsiao, L. C., Lin, S. H. and Ho, L. T. 1999. Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: Results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med 16:749–754.
   PubMed Web of Science ®Google Scholar
• Ikeda, H., Taketomi, S., Sugiyama, Y., Shimura, Y., Sohda, T., Meguro, K. and Fujita, T. 1990. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40:156–162.
   PubMed Web of Science ®Google Scholar
• Jain, M. K. and Ridker, P. M. 2005. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977–987.
   PubMed Web of Science ®Google Scholar
• Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K. and Tobe, K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792.
   PubMed Web of Science ®Google Scholar
• Kakadiya, J. and Shah, N. 2010. Investigation of effects of pioglitazone, glimepiride, nobivolol, valsartan, and hesperidine on glucose, HbA1c and lactate dehydrogenase in isoproterenol-induced myocardial infarction in normal and diabetic rats. JITPS 1:144–151.
   Google Scholar
• Kalo, M. S. 2009. Effect of cholesterol biosynthesis inhibitor on some biochemical parameters in normal male rats. Iraqi J Vet Sci 23:5–12.
   Google Scholar
• Kanda, M., Satoh, K. and Ichihara, K. 2003. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 26:1681–1684.
   PubMed Web of Science ®Google Scholar
• Kannappan, S. and Anuradha, C. V. 2009. Insulin sensitizing actions of fenugreek seed polyphenols, quercetin and metformin in a rat model. Indian J Med Res 129:401–408.
   PubMed Web of Science ®Google Scholar
• Khan, T., Hamilton, M. P., Mundy, D. I., Chua, S. C. and Scherer, P. E. 2009. Impact of simvastatin on adipose tissue: Pleiotropic effects in vivo. Endocrinology 150:5262–5272.
   PubMed Web of Science ®Google Scholar
• Koh, K. K., Quon, M. J., Lee, S. J., Han, S. H., Ahn, J. Y., Kim, J. A., Chung, W. J., Lee, Y. and Shin, E. K. 2007. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care 30:1605–1607.
   PubMed Web of Science ®Google Scholar
• Lai, I. R., Chang, K. J., Tsai, H. W. and Chen, C. F.. 2008. Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Transplantation 85:732–738.
   PubMed Web of Science ®Google Scholar
• Lee, M. Y., Lee, E. Y., Lee, B. J., Won, C. S., Koh, J. H., Shin, J. Y., Shin, Y. G., Cho, B. P. and Chung, C. H. 2007. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J 48:301–307.
   PubMed Web of Science ®Google Scholar
• Lumeng, C. N., Bodzin, J. L. and Saltiel, A. R. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–184.
   PubMed Web of Science ®Google Scholar
• Majithiya, J. B., Paramar, A. N. and Balaraman, R. 2005. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 66:150–161.
   PubMed Web of Science ®Google Scholar
• Malinowski, J. M. and Bolesta, S. 2000. Rosiglitazone in the treatment of Type 2 diabetes mellitus: A critical review. Clin Ther 22:1151–68; discussion 1149.
   PubMed Web of Science ®Google Scholar
• Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Mital, S., Magneson, A., Loke, K. E., Liao, J., Forfia, P. R. and Hintze, T. H. 2000. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol 36:248–254.
   PubMed Web of Science ®Google Scholar
• Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J. and DeFronzo, R. A. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab 87:2784–2791.
   PubMed Web of Science ®Google Scholar
• Miyazaki, Y., Mahankali, A., Wajcberg, E., Bajaj, M., Mandarino, L. J. and DeFronzo, R. A. 2004. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab 89:4312–4319.
   PubMed Web of Science ®Google Scholar
• Mohamadin, A. M., Elberry, A. A., Abdel Gawad, H. S., Morsy, G. M. and Al-Abbasi, F. A. 2011. Protective effects of simvastatin, a lipid-lowering agent, against oxidative damage in experimental diabetic rats. J. Lipids. 2011:167958. Epub 2011:Dec 6 (doi:10.1155/2011/167958).
   PubMedGoogle Scholar
• Moore, M. C., Cherrington, A. D., Mann, S. L. and Davis, S. N. 2000. Acute fructose administration decreases the glycemic response to an oral glucose tolerance test in normal adults. J Clin Endocrinol Metab 85:4515–4519.
   PubMed Web of Science ®Google Scholar
• Motoshima, H., Wu, X., Sinha, M. K., Hardy, V. E., Rosato, E. L., Barbot, D. J., Rosato, F. E. and Goldstein, B. J. 2002. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: Effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667.
   PubMed Web of Science ®Google Scholar
• Murdock, D. K., Jansen, D., Juza, R. M., Kersten, M., Olson, K. and Hendricks, B. 2006. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. WMJ 105:22–25.
   PubMedGoogle Scholar
• Psyrogiannis, A., Kyriazopoulou, V., Symeonidis, A., Leotsinidis, M. and Vagenakis, A. G. 2003. Relative iron “overload” in offspring of patients with type 2 diabetes mellitus: A new component in the conundrum of insulin resistance syndrome? Hormones (Athens) 2:161–168.
   PubMedGoogle Scholar
• Satoh, K., Keimatsu, N., Kanda, M., Kasai, T., Takaguri, A., Sun, F. and Ichihara, K. 2005. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 28:2092–2095.
   PubMed Web of Science ®Google Scholar
• Schaefer, J. R., Schweer, H., Ikewaki, K., Stracke, H., Seyberth, H. J., Kaffarnik, H., Maisch, B. and Steinmetz, A. 1999. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177–184.
   PubMed Web of Science ®Google Scholar
• Stanhope, K. L. and Havel, P. J. 2008. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol 19:16–24.
   PubMed Web of Science ®Google Scholar
• Stefan, N., Vozarova, B., Funahashi, T., Matsuzawa, Y., Weyer, C., Lindsay, R. S., Youngren, J. F., Havel, P. J., Pratley, R. E., Bogardus, C. and Tataranni, P. A. 2002. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884–1888.
   PubMed Web of Science ®Google Scholar
• Stephens, J. M. and Pekala, P. H. 1991. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 266:21839–21845.
   PubMed Web of Science ®Google Scholar
• Suganami, T., Tanimoto-Koyama, K., Nishida, J., Itoh, M., Yuan, X., Mizuarai, S., Kotani, H., Yamaoka, S., Miyake, K., Aoe, S., Kamei, Y. and Ogawa, Y.. 2007. Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 27:84–91.
   PubMed Web of Science ®Google Scholar
• Teruel, T., Hernandez, R., Rial, E., Martin-Hidalgo, A. and Lorenzo, M. 2005. Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia 48:1180–1188.
   PubMed Web of Science ®Google Scholar
• Thorburn, A. W., Storlien, L. H., Jenkins, A. B., Khouri, S. and Kraegen, E. W. 1989. Fructose-induced in vivoinsulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 49:1155–1163.
   PubMed Web of Science ®Google Scholar
• Vega, G. L., Clark, L. T., Tang, A., Marcovina, S., Grundy, S. M. and Cohen, J. C. 1998. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 39:228–232.
   PubMed Web of Science ®Google Scholar
• Vijay, S. K., Mishra, M., Kumar, H. and Tripathi, K. 2009. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in Type-2 diabetes. Acta Diabetol 46:27–33.
   PubMed Web of Science ®Google Scholar
• Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L and Ferrante, A.W.. Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808.
   PubMed Web of Science ®Google Scholar
• Westerink, J. and Visseren, F. L. 2011. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 10:13.
   PubMed Web of Science ®Google Scholar
• Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E. and Tataranni, P. A. 2001. Hypoadiponectinemia in obesity and Type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935.
   PubMed Web of Science ®Google Scholar
• Xu, P., Zhang, X. G., Li, Y. M., Yu, C. H., Xu, L. and Xu, G. Y. 2006. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B 7:627–633.
   PubMedGoogle Scholar
• Yadav, H., Jain, S., Yadav, M., Sinha, P. R., Prasad, G. B. and Marotta, F. 2009. Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats. Dig Liver Dis 41:500–508.
   PubMedGoogle Scholar
• Yki-Järvinen, H. 2004. Thiazolidinediones. N Engl J Med 351:1106–1118.
   PubMed Web of Science ®Google Scholar